[Advances in Zika vaccines]

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Zika virus (ZIKV) is transmitted by Aedes mosquitoes, affecting two billion people globally.
• ZIKV outbreaks, particularly in the Americas, pose significant public health risks, especially to pregnant women and fetuses.
• ZIKV infection is linked to severe outcomes like congenital microcephaly and Guillain-Barre syndrome, with no current effective treatments or vaccines.

Purpose of the Study:

• To review the current landscape and advancements in Zika virus (ZIKV) vaccine development.
• To highlight the potential of DNA vaccines as a promising approach against ZIKV.

Main Methods:

• Review of existing literature on ZIKV vaccines.
• Analysis of the characteristics and advantages of DNA vaccine technology for ZIKV.

Main Results:

• The first Zika DNA vaccine demonstrated complete protection and induced high antibody titers.
• DNA vaccines offer advantages such as simplified design, safe production, and safety for adults and fetuses.
• Progress has been made in developing both traditional and emerging vaccine candidates for ZIKV.

Conclusions:

• Zika virus (ZIKV) necessitates urgent development of effective vaccines and treatments.
• DNA vaccines represent a safe and promising platform for ZIKV prevention.
• Ongoing research into various vaccine types shows progress towards controlling ZIKV transmission and its devastating effects.